bodyType

customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

hooksAmpRedirectArticle

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

paywallTypes

createdDate

publishedDate

sponsorType

urlAlias

moreOnThisArticles

commentCount

authorLocations

authors

corrections

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

articleSpeeches

socialHeadline

headline

images

flag

firstTopic

glossary

flattenTypeIds

image

relatedLinks

relatedNewsletters

__typename

sponsor

pdfFiles

seriesReverseOrder

series

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

readingTime

customTimezone

liveContents

A highly sensitive test that detects traces of disease in the bone marrow of patients with a rare and aggressive type of blood cancer could help double their chances of survival, a new trial has found.
The 10-minute procedure – which involves an injection in the hip bone every three months – identified signs of acute myeloid leukaemia (AML) returning in patients before it showed in blood tests.
This gives doctors a “window of opportunity” to treat people while they are still well, researchers said.
Experts hope the test could become routine care for patients with AML.
AML is a cancer that causes the bone marrow to produce a large number of abnormal blood cells. Tens of thousands of people are diagnosed around the world each year.
The risk of developing the disease increases with age and it is most common in people over 75. After treatment, patients are usually seen every few weeks for blood tests.
“There’s a significant risk for these patients that the leukaemia is going to come back again, and that’s normally detected by a deterioration in the blood tests,” said professor Nigel Russell, honorary consultant at Guy’s and St Thomas’ NHS Foundation Trust in the UK and the chief investigator in the trial.
“Sometimes it can happen very quickly, and sometimes it can happen over a period of weeks. So normally, the patient comes along, has a blood test done, the blood test is OK, they’re sent off again. That’s the procedure that’s been the case for many years.
“But the trial included these extra tests in the bone marrow every three months to detect if there’s any evidence of what we call residual leukaemia; it’s such a low level that the blood tests are normal, but the disease can still be present at very low levels in the bone marrow.”

The bone marrow test takes around 10 minutes and is performed under local anaesthetic, with a hollow needle inserted into the patient’s hip bone to take the sample.
“It detects the RNA present in the leukaemia cells, but not present in normal cells,” Russell added, referring to ribonucleic acid, a crucial molecule in all living organisms that plays a vital role in carrying genetic information.
For the study, led by King’s College London and published in The Lancet Haematology, patients were screened for mutations in two genes, NPM1 and FLT3, which are common in younger people with AML.
The trial involved 637 people who were in remission from AML who, over three years, either received standard monitoring or standard monitoring with additional bone marrow tests every three months.
“It was about one-third of patients that really benefited from this approach that had a doubling of their survival, which was a massive improvement in outcome for these patients,” Russell said.
“And really, it’s quite a simple extra procedure to have done. Since the results of the trial have become available, this sort of technology is now part of what we call the standard of care.
“The important thing is that it gives you a window of opportunity to treat the patient before they become unwell. Because if the patient relapses, they can become quite unwell very quickly, and their blood counts are very abnormal. They have to come into hospital, and they have to have further treatment of chemotherapy, and then possibly go on to a bone marrow transplant.
“The advantage of detecting it early is the patients can have these treatments when they’re still well – even potentially as an outpatient, because their blood tests are normal. They don’t need to come into hospital as an emergency and they’re starting with a fresh start, really, rather than being ill again.”
Jane Leahy, 51, is one of the patients who took part in the trial.
She was diagnosed with AML in 2014, at the age of 41, and after chemotherapy went into remission the following April.
The mother-of-two had her bone marrow tested as part of the trial, which picked up abnormalities a few months later.
After restarting treatment, the bone marrow test results also showed the chemotherapy was not working, with a stem cell transplant her only chance of going into remission again.
“Without testing, I wouldn’t have gone on to have my transplant, because my blood showed I was still in remission,” Leahy said.

Nine years after her bone marrow transplant – which was donated by her sister – Leahy is still in remission.
“It’s pretty scary, really, when I think about potentially what could have happened. And there were so many things throughout my treatment journey, it felt like the stars were aligning.
“I feel incredibly lucky.”
Leahy said bone marrow testing gives doctors “more time”, adding: “The time is always critical, because it’s so acute and so aggressive. And a lot of people die from AML before they get to treatment, because it’s just diagnosed so late.
“So it just gives more time, more opportunities to try different treatment approaches and pick it up earlier, before it becomes too late to do anything about.”
Like what you read? Follow SCMP Lifestyle on Facebook, X and Instagram. You can also sign up for our eNewsletter here.


What is cancer prehabilitation? How patients are getting a head start in recovery

How walking in Hong Kong is helping with cancer recovery and mental health

How mono or ‘the kissing disease’ may increase your risk for other illnesses

Do dogs like music? Experts weigh in on how songs affect our furry friends

Wellness

New bone marrow test doubles AML blood cancer survival chances

AML (acute myeloid leukaemia) is a cancer that causes the bone marrow to produce a large number of abnormal blood cells, like these pictured in purple. Illustration: Shutterstock

Professor Nigel Russell was the chief investigator in the trial. Photo: vjhemonc.com

Jane Leahy was diagnosed with AML in 2014. Photo: Jane Leahy

Emilia Clarke had 2 strokes in her 20s, so what causes them and how to recognise one?

Emilia Clarke suffered her first stroke at the age of 24, and another two years later. Photo: AP

Emilia Clarke as Daenerys Targaryen in Game of Thrones. The actress suffered her first stroke at the age of 24, and another two years later, before establishing a charity, SameYou, to raise awareness of strokes and support those with brain injuries and strokes. 
Photo: HBO

Clarke suffered a second aneurysm two years after her first. Photo: Instagram/emilia_clarke

Dr Gary Lau is director of the stroke research and prevention group that led the study at the University of Hong Kong. Photo: University of Hong Kong 

A typical Chinese diet is particularly high in sodium. Photo: Shutterstock

Someone who smokes 20 cigarettes a day carries a six-fold risk of having a stroke. Photo: Jelly Tse

Phthalate DEHP, chemical in everyday household items, linked to 1 in 8 heart disease deaths

DEHP, a phthalate chemical, can be ingested after it is broken down into microscopic particles as part of the everyday use of the items it is contained in. Photo: Shutterstock

Exposure to phthalate chemical Di(2-ethylhexyl)phthalate, or DEHP, used in everyday household goods and to soften plastic, contributed to more than 356,000 deaths from cardiovascular disease worldwide in 2018, a study shows. Photo: Shutterstock

DEHP is used to make food containers, medical equipment and to soften plastic, and is also found in pipes and in cosmetics, sprays, detergents and solvents. Photo: Shutterstock

Sara Hyman, the study’s lead author, says the findings add to the vast body of evidence that phthalates present a tremendous danger to human health. Photo: LinkedIn/Sara Hyman

How did Singapore resident beat cancer 3 times? Her secret to overcoming fear of the disease

Singapore resident Aparna Suri, who has been diagnosed with cancer three times, pictured  between chemotherapy sessions in 2024. Photo: Aparna Suri

Suri with a shaved head in 2024 after losing hair from undergoing mantle radiation treatment. Photo: Aparna Suri 

Suri with her husband on holiday in Bali, Indonesia, in 2022. Photo: Aparna Suri

Suri smiles at a Diwali party in 2023, shortly after she had received her third cancer diagnosis. Photo: Aparna Suri

Suri with two of her paintings in 2022. She took up new hobbies, including sketching, painting and cooking, as a distraction from fighting cancer. Photo: Aparna Suri

Suri did not cook until after her first cancer diagnosis. She now delights in hosting friends for meals and perfecting recipes. Photo: Aparna Suri

Suri eats more healthy foods, including salads. Photo: Aparna Suri

Suri (centre) took part in the Great Eastern Women’s Run in 2024. Photo: Aparna Suri

Swollen, puffy face? You might have ‘moon face’. Experts explain, share how to reduce it

“Moon face” or “cortisol face”, a condition in which the face appears swollen and puffy, is a health concern that has been popping up online. Photo: Instagram/mamamiaaus

The most common cause of moon face is long-term use of corticosteroid medications. Photo: Shutterstock

Lifestyle

Health & Wellness

Health

The 10-minute procedure identified signs of acute myeloid leukaemia (AML) returning in patients before it showed in blood tests


The 10-minute procedure identified signs of acute myeloid leukaemia (AML) returning in patients before it showed in blood tests.


New bone marrow test doubles AML blood cancer survival chances

.css-1c6uqr6{color:inherit;font-weight:inherit;font-size:inherit;font-family:inherit;line-height:inherit;overflow-wrap:break-word;}The 10-minute procedure identified signs of acute myeloid leukaemia (AML) returning in patients before it showed in blood tests

The 10-minute procedure identified signs of acute myeloid leukaemia (AML) returning in patients before it showed in blood tests